Navigation Links
Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
Date:3/24/2017

WESTLAKE VILLAGE, Calif., March 24, 2017 /PRNewswire/ -- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, today announced that Richard Peterson will join the company as Chief Financial Officer, effective March 24.  

Peterson, who brings more than two decades of global financial experience, will succeed John Smither, who is retiring at the end of April but will continue to serve Sienna in an advisory capacity. Peterson joins Sienna from Novan, Inc., where he served as Chief Financial Officer for the pharmaceutical dermatology company. Previously, he was the Chief Financial Officer and Treasurer of Medicis Pharmaceutical Corporation until the company's acquisition in 2012 by Valeant Pharmaceuticals International, Inc., for $2.6 billion.

"We are pleased to welcome Ric to Sienna and look forward to his contributions as we advance our robust and diversified pipeline of topical biotech products," said Frederick C. Beddingfield III, M.D., Ph.D., Sienna's President and Chief Executive Officer. "Ric is an accomplished financial leader with a proven track record of creating value for medical dermatology and aesthetic companies that develop and market industry-leading products."

During Peterson's tenure at Medicis, the company achieved significant growth in revenue and profitability with a portfolio of top-selling medical and aesthetic products including SOLODYN® for acne and Restylane® and Dysport® for the treatment of facial wrinkles. Prior to Medicis, Peterson was a Senior Financial Auditor with PricewaterhouseCoopers. He holds a Bachelor of Science in accountancy from Arizona State University.

"I am delighted to join the Sienna team at such an exciting time for the company," Peterson said. "Sienna is poised, with innovative topical platform technologies, to address significant unmet needs and fundamentally change the treatment of dermal inflammation and aesthetic skin conditions, and I am eager to contribute to the company's success."

Sienna is developing first-in-class late-stage clinical candidates to create targeted safe and effective topical therapies that treat conditions such as psoriasis, atopic dermatitis, pruritus, acne vulgaris and unwanted light-pigmented hair with limited systemic exposure.

"I would like to recognize and thank John Smither, who has worked tirelessly to help establish Sienna and expand our portfolio," Dr. Beddingfield said. "John has been instrumental in securing financing and building a stellar finance team that sets Sienna up for success as we move forward. We are pleased that we will continue to benefit from his counsel."

About Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals, Inc. is a medical dermatology and aesthetics company focused on developing safe and effective targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Sienna is led by a team of accomplished scientists, clinicians and business leaders who have developed and commercialized leading global brands in dermatology and aesthetics. Sienna is building an innovative, diversified pipeline to address unmet needs in medical dermatology and aesthetics. The company's investors include: ARCH Venture Partners; Partner Fund Management; Altitude Life Science Ventures; Venvest Capital; Two River; and several prominent medical dermatology and aesthetics industry luminaries. Find more information at www.siennabio.com.

SOLODYN® is a registered trademark of Valeant Pharmaceuticals International, Inc.; Restylane® and Dysport® are registered trademarks of Galderma.

Contact:
Ryan Irvine, Ph.D.
Vice President, Head of Medical Affairs
rirvine@siennabio.com

Investors:
Derek Cole
720.785.4497
derek.cole@IRadvisory.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/richard-peterson-joins-sienna-biopharmaceuticals-as-chief-financial-officer-300428999.html


'/>"/>
SOURCE Sienna Biopharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Longitude Capital Promotes Josh Richardson, M.D., To Managing Director
2. Cold Chain Technologies Promotes Richard Formato to Principal Technologist
3. Neuralstem Appoints Richard Daly as President and Chief Executive Officer
4. Former Senior Janssen Executive Dr. Richard C. Siegel, PhD Joins NDA Partners as a Premier Expert Consultant
5. Kiadis Pharma Appoints Dr. Vincent Brichard to its Supervisory Board
6. Richard Rubenstein, MD Selected As One Of South Floridas Top Doctors!
7. 23andMe to Create Therapeutics Group, Appoints Scientific Luminary, R&D Executive Richard Scheller, Ph.D. to Lead
8. Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund
9. Y-Prime Names Richard Gastineau Chief Operating Officer
10. Spherix Appoints Richard Cohen as Chief Financial Officer
11. Cleveland Heart Founder Dr. Charles Richardson Appointed to ReliantHeart Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2018)... Calif. and WESTMINSTER, Colo. (PRWEB) , ... ... ... Predicine and Flagship Biosciences are excited to announce a strategic venture. The ... cTA® digital pathology platform provides complimentary and comprehensive biomarker profiling to empower ...
(Date:9/15/2018)... ... ... recognized public accounting and consulting firm Cherry Bekaert LLP (“the Firm”) congratulates ... her appointment to Launch Tennessee’s Board of Directors. , Patrick has been ... Nashville practice in December 2017 . In this role, she oversees the execution of ...
(Date:9/12/2018)... Wash. (PRWEB) , ... September 11, 2018 , ... ... is proud to add flat sheet Forward Osmosis (FO) membranes from Fluid Technology ... FO membranes manufactured by FTS H2O are constructed from cellulose triacetate (CTA) material. ...
(Date:9/7/2018)... ... September 06, 2018 , ... ... commercialization, is releasing the agenda for its upcoming user conference. , This ... discussing the latest challenges, opportunities, and approaches to regulatory compliance and quality management. ...
Breaking Biology Technology:
(Date:9/1/2018)... ... , ... Right this minute, Frenchman Ben Lecomte is hard at work on his second ocean ... on a new challenge: going from Tokyo to San Francisco, churning his limbs eight hours ... support boat. As the first expedition of its kind, The Swim is far more than ...
(Date:8/31/2018)... and BOSTON, Mass. (PRWEB) , ... August 30, 2018 , ... ... Product and Customer Success. Jason has more than 20-years of telecommunications experience and over ... Sales at Appia Communications, which was acquired by CallTower in early 2018. , ...
(Date:8/31/2018)... and CARDIFF, Wales (PRWEB) , ... August 30, ... ... Agency. Martha Sanchez, senior scientist, IBM Research. Jacklyn Novak, infrared materials engineer, LightPath ... Katherine Johnson, the NASA mathematician who just celebrated her 100th birthday. Today, they ...
Breaking Biology News(10 mins):